Suchergebnisse - (Person:"Wang, Ming")

PubPharm (108)

1

DDR1/2 enhance KIT activation and imatinib resistance of primary and secondary KIT mutants in gastrointestinal stromal tumors

enthalten in: Molecular carcinogenesis | 2024

von Liu, A. | Zhang, S. | Wang, M. | +14

2

Drugs in the GIST Field (Therapeutic Targets and Clinical Trial Staging)

enthalten in: Current drug delivery | 2024

von Huang, C. | Ma, X. | Wang, M. | +1

3

SPRY4 inhibits and sensitizes the primary KIT mutants in gastrointestinal stromal tumors (GISTs) to imatinib

enthalten in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association | 2023

von Li, S. | Zhao, S. | Liang, N. | +13

4

Discovery of 3-pyrazolyl-substituted pyrazolo[1,5-a]pyrimidine derivatives as potent TRK inhibitors to overcome clinically acquired resistance

enthalten in: European journal of medicinal chemistry | 2022

von Gong, Y. | Wu, F. | Wang, M. | +4

5

Exploring the kinase-inhibitor fragment interaction space facilitates the discovery of kinase inhibitor overcoming resistance by mutations

enthalten in: Briefings in bioinformatics | 2022

von Wang, Z. | Wang, M. | Wang, F. | +4

6

Clinicopathologic Characteristics and Prognosis of PDGFRA-Mutant Gastrointestinal Stromal Tumors : A Large-Scale, Multi-Institutional, Observational Study in China

enthalten in: Advances in therapy | 2022

von Zhang, P. | Wang, M. | Li, J. | +16

7

Dysregulation of CXCL14 promotes malignant phenotypes of esophageal squamous carcinoma cells via regulating SRC and EGFR signaling

enthalten in: Biochemical and biophysical research communications | 2022

von Guo, J. | Chang, C. | Yang, L. | +8

8

Combination of Bevacizumab and Osimertinib in Patients with EGFR T790M-Mutated Non-small Cell Lung Cancer

enthalten in: Clinical drug investigation | 2022

von Liu, S. | Pan, T. | Wang, M. | +3

9

NEFL promotes invasion and migration of esophageal squamous carcinoma cells via the EGFR/AKT/S6 pathway

enthalten in: Yi chuan = Hereditas | 2022

von Fan, Z. | Yang, L. | Zhang, N. | +9

10

Antibody-drug Conjugate PCMC1D3-Duocarmycin SA as a Novel Therapeutic Entity for Targeted Treatment of Cancers Aberrantly Expressing MET Receptor Tyrosine Kinase

enthalten in: Current cancer drug targets | 2022

von Hudson, R. | Yao, H. | Suthe, S. | +2

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[11]